Together with MPTP, 6-OHDA is the most widely utilized neurotoxin to create PD models. In contrast to MPTP, 6-OHDA does not readily cross the BBB. Therefore, direct injection of 6-OHDA into the brain of test animals is necessary [14]. Currently, the mode of action is thought to be via increased oxidative stress and mitochondrial dysfunction, although the exact mechanism remains under discussion. It is clear, however, that administration of 6-OHDA leads to its conversion into ROS [22], a reduction of the antioxidant glutathione (GSH) and antioxidant enzyme superoxide dismutase (SOD) [23], elevated levels of iron in the SN [24] and inhibition of complex I and IV in the mitochondria [25], which leads to further oxidative stress. 6-OHDA lesions share common mechanisms of action with PD and is therefore regarded as an excellent model [14].